Introduction: Brown recluse spider bites are encountered commonly in endemic areas of North and South America. Loxosceles reclusa is the species of Loxosceles most commonly seen in the states of MO, KS, OK, TX, AK, LA, KY, TN, MS, AL and parts of IL, IA, IN and GA. The incidence of hemolytic anemia with systemic loxoscelism in the USA seems to be significantly higher and more severe than the incidence and severity reported in studies from South America (13%-15% incidence). In our 6 cases of loxoscelism associated with severe hemolysis, we noticed that there are signs and symptoms that could be helpful to guide the follow up and facilitate early diagnosis.

Method: We reviewed 6 cases of hemolytic anemia from Loxoscelism treated at the University of Missouri Hospitals. Of these 6 cases 4 were treated within 1 year. All of the cases presented with systemic and cutaneous manifestations. Each patient was initially treated symptomatically and discharged without a close follow up. This resulted in delayed presentations with symptoms of severe hemolytic anemia associated with significant morbidity [Syncope (1), Syncope with fracture (1), Hypotension needing ICU care (1), Necrotizing fasciitis (1), and severe hepatosplenomegaly with hyperbilirubinemia (1)]. We have summarized the systemic symptoms, peripheral blood smear and laboratory findings that correlate with hemolytic anemia.

Results:Patients presented with Nausea (6/6), Vomiting (5/6), Fever (5/6), and Target lesion (6/6) within 48 hours after spider bite [Table 1]. Severe hemolysis developed at a median of 6.5 days after the spider bite. DAT was positive for IgG and C3 in all of the cases. Peripheral smear findings included leukocytosis with toxic granulations, Dohle bodies and left shift, Nucleated RBC, anisopoikilocytosis with some schistocytes, hemophagocytosis and normal to decreased platelets [Figure 1] [Figure 3]. When not recognized patients presented with sudden and severe hemolysis (median drop in Hb =7.5 g/dL) [Table2] resulting in hospitalization with severe morbidity (Figure 2).

Table 1
Initial PresentationSignificant Morbidity
Patient 1 Nausea and vomiting.
Fever.
Diffuse rash, RUQ pain
Target lesion on back 
Severe Jaundice
Hepatomegaly
Splenomegaly 
Patient 2 Nausea, vomiting and diarrhea.
Fever
Target lesion on left arm 
Syncope
Ankle fracture 
Patient 3 Nausea, fatigue and malaise.
Target lesion on right back 
Recurrent syncope 
Patient 4 Nausea, Vomiting
Fever
Target lesion right arm. 
Severe Hypotension
ICU care 
Patient 5 Nausea, dry heaves
Fever.
Thigh pain
Target lesion right thigh. 
Necrotizing fasciitis
Fasciotomy 
Patient 6 Nausea, vomiting and fatigue.
Fever.
Target lesion right shoulder.
 
 
Initial PresentationSignificant Morbidity
Patient 1 Nausea and vomiting.
Fever.
Diffuse rash, RUQ pain
Target lesion on back 
Severe Jaundice
Hepatomegaly
Splenomegaly 
Patient 2 Nausea, vomiting and diarrhea.
Fever
Target lesion on left arm 
Syncope
Ankle fracture 
Patient 3 Nausea, fatigue and malaise.
Target lesion on right back 
Recurrent syncope 
Patient 4 Nausea, Vomiting
Fever
Target lesion right arm. 
Severe Hypotension
ICU care 
Patient 5 Nausea, dry heaves
Fever.
Thigh pain
Target lesion right thigh. 
Necrotizing fasciitis
Fasciotomy 
Patient 6 Nausea, vomiting and fatigue.
Fever.
Target lesion right shoulder.
 
 

Figure 1:

Peripheral Smear Findings of Systemic Loxoscelism

Figure 1:

Peripheral Smear Findings of Systemic Loxoscelism

Close modal
Figure 2:

Significant Morbidity from Systemic Loxoscelism

Figure 2:

Significant Morbidity from Systemic Loxoscelism

Close modal
Figure 3:

Peripheral smear findings

Figure 3:

Peripheral smear findings

Close modal

Table 2
Patient 1Patient 2Patient 3Patient 4Patient 5Patient 6Median
Age 34 31 21 25 21 22 23.5 
Days after bite to lowest Hemoglobin 6.5 
Baseline Hb (g/dL) 11 12 15 13 13.8 15.7 13.4 
Lowest Hb (g/dL) 5.7 6.6 8.4 5.85 
MCV with lowest Hb (fL) 70 107 100 90 96.6 101 98.3 
WBC (103/µL) 12.6 42 32.3 14.5 33.4 26.6 29.45 
Platelets (103/µL) 160 141 234 64 261 576 197 
LDH (unit/L) hemolysed 2080 951 1348 744 346 951 
T. Bili (mg/dL) 35.4 13.2 1.8 3.7 7.4  
D. Bili (mg/dL) >10 9.2 .3 .5 0.3 1.4  
Ind. Bili (mg/dL)  3.9 4.7     
AST (unit/L) 100 52 25 201 120 156  
ALT (unit/L) 86 95 19 91 104 294  
Alk phos (unit/L) 94 88 67 36 160 159  
Blood group A Pos A Pos O Pos B Pos O Pos   
Patient 1Patient 2Patient 3Patient 4Patient 5Patient 6Median
Age 34 31 21 25 21 22 23.5 
Days after bite to lowest Hemoglobin 6.5 
Baseline Hb (g/dL) 11 12 15 13 13.8 15.7 13.4 
Lowest Hb (g/dL) 5.7 6.6 8.4 5.85 
MCV with lowest Hb (fL) 70 107 100 90 96.6 101 98.3 
WBC (103/µL) 12.6 42 32.3 14.5 33.4 26.6 29.45 
Platelets (103/µL) 160 141 234 64 261 576 197 
LDH (unit/L) hemolysed 2080 951 1348 744 346 951 
T. Bili (mg/dL) 35.4 13.2 1.8 3.7 7.4  
D. Bili (mg/dL) >10 9.2 .3 .5 0.3 1.4  
Ind. Bili (mg/dL)  3.9 4.7     
AST (unit/L) 100 52 25 201 120 156  
ALT (unit/L) 86 95 19 91 104 294  
Alk phos (unit/L) 94 88 67 36 160 159  
Blood group A Pos A Pos O Pos B Pos O Pos   

Discussion: Systemic loxoscelism from Loxosceles reclusa in USA is associated with a high incidence of severe hemolytic anemia. Increased awareness of the delayed presentation with hemolysis after initial signs of systemic loxoscelism could avoid life threatening events. Initial symptoms developed within 48 hours of the spider bite and led to medical attention in all of the reported cases.

With appropriate follow up, peripheral smear review and labs at 5-7 days after the spider bite most of the cases would have been recognized early and could have potentially avoided life threatening complications.

The different species of Loxosceles prevalent in South America could explain the difference in the incidence of hemolytic anemia. Studies from Brazil have reported the use of antivenom in about 50% of loxoscelism cases. Effectiveness of antivenom is not established and is seldom used in the USA but, could account for some differences in the incidence of hemolysis.

Disclosures

No relevant conflicts of interest to declare.

Author notes

*

Asterisk with author names denotes non-ASH members.

Sign in via your Institution